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Objectives. This study examined the effect of low dose aspirin on 
cardiorenal and neurohumorai function and on the acute hemo- 
dynamic response to enalaprilat in a canine model of heart 
failure. 
Background. Low dose aspirin is frequently prescribed for 
patients with systolic dysfunction who also benefit from 
angiotensin-converting e zyme inhibition. Although igh doses of 
potent cyclo-oxygenase inhibitors cause fluid retention and vaso- 
constriction and antagonize the effects of angiotensin-converting 
enzyme inhibitors, the effects of low dose aspirin in heart failure 
are unknown. 
Methods,. A model of heart failure was produced in 11 mongrel 
dogs by rapid ventricular pacing (250 beats/rain for 12 to 14 days). 
Five dogs received 325 mg aspirin/day for the final 4 days of 
pacing before the acute experiment; six control dogs received no 
aspirin. Cardiorenal and neurohumoral function was measured 
during chloralose anesthesia. Hemodynamic and renal responses 
to enalaprilat were assessed. 
Results. Both groups demonstrated severe heart failure with 
decreased cardiac output; increased atrial pressures and systemic 
resistance; activation of plasma renin activity, aldosterone and 
atrial natriuretic factor; and sodium retention. Low dose aspirin 
had no detrimental effect on cardiorenal or neurohumoral func- 
tion. Mean arterial pressure, pulmonary capillary wedge pressure 
and systemic vascular esistance decreased to a similar degree 
with enalaprilat in both groups. There was no difference between 
the groups with respect o renal response to enalaprilat. 
Conclusions. The present study demonstrates that low dose 
aspirin has no adverse ffect on hemodynamic, neurohumoral or
renal function in heart failure. Furthermore, aspirin has no 
adverse ffect on the acute response to enalaprilat. These findings 
suggest that there is no contraindication to concomitant treat- 
ment with low dose aspirin and angiotensin-converting e zyme 
inhibitors in humans with heart failure. 
(J Am Coil Cardiol 1995;25:1445-50) 
Multiple studies (1-5) have documented the beneficial 
effects of angiotensin-converting e zyme inhibition therapy 
on morbidity and mortality in patients with ventricular 
systolic dysfunction in the presence and absence of symp- 
toms of congestive heart failure. Patients with or at risk for 
concomitant coronary artery disease may also benefit from 
therapy with low dose aspirin because it has been demon- 
strated to be effective for the primary and secondary 
prevention of cardiac events (6-11). Thus, therapy with both 
angiotensin-converting e zyme inhibitors and low dose as- 
pirin may frequently be recommended for patients with 
ventricular dysfunction and coronary artery disease. Al- 
though the mechanisms of actions of angiotensin-converting 
enzyme inhibitors are multiple, recent investigations (12,13) 
have emphasized the non-angiotensin II mechanisms that 
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mediate the action of angiotensin-converting e zyme inhib- 
itors, including the inhibition of bradykinin metabolism and 
subsequent enhancement of vasodilatory prostaglandin gen- 
eration. 
The potential interaction of aspirin and angiotensin- 
converting enzyme inhibitor therapies is of clinical interest 
because previous tudies (14-16) have reported the detrimen- 
tal effects of large doses of potent prostaglandin i hibitors on 
hemodynamic and renal function in patients with heart failure. 
Previous tudies (16-18) have also reported antagonism ofthe 
beneficial effects of angiotensin-converting e zyme inhibitors 
in hypertension or heart failure by large doses of potent 
prostaglandin inhibitors. Although not specifically investi- 
gated, the effect of small doses of prostaglandin i hibitors on 
hemodynamic and renal function in heart failure was thought 
to be insignificant. However, Hall et al. (19) recently reported 
that a single dose of aspirin (325 rng) blunted the acute 
hemodynamic effect of enalaprilat in patients with heart fail- 
ure. 
In recognition of the lack of data regarding the effect of low 
dose aspirin in severe heart failure and the provocative findings 
of Hall et al., the current study was designed to examine the 
effect of low dose (325 mg/day for 4 days) aspirin on cardio- 
renal and neurohumoral function and on the acute hemody- 
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namic response to enalaprilat ina canine model of severe heart 
failure produced by rapid ventricular pacing. We hypothesized 
that low dose aspirin would not have a detrimental effect on 
hemodynamic, neurohumoral orrenal function in severe heart 
failure and would not attenuate the acute hemodynamic 
response to enalaprilat. 
Methods 
Canine model of chronic severe heart failure. An experi- 
mental model of chronic severe heart failure was produced in 
11 male mongrel dogs (17 to 25 kg) by rapid ventricular pacing 
at 250 beats/min for 12 to 14 days, as previously described 
(20-23). The experimental protocol was approved by the Mayo 
Clinic Institutional Animal Care and Use Committee and was 
conducted according to the guiding principles of the American 
Physiological Society. Permanent programmable pacemakers 
(modified model 8426, Medtronic) were implanted uring 
sodium pentobarbital (30 mg/kg body weight) anesthesia. A 
left thoracotomy and 1- to 2-cm pericardotomy were per- 
formed. A screw-in epicardial pacemaker lead was implanted 
in the right ventricular epicardium and tunneled subcutane- 
ously to the pulse generator, which was implanted in the 
dorsal neck. The incisions were closed in layers, and the 
dogs received antibiotic drugs for 3 days after the proce- 
dure. The animals were allowed to recover for 2 weeks. 
Throughout the study the dogs were fed standard laboratory 
dog chow (Laboratory Canine Diet 5506, Purina Mills). A 
baseline two-dimensional guided M-mode echocardiogram 
was acquired for assessment of ventricular size and systolic 
function. Ejection fraction was calculated using the method 
of Quinones et al. (24). Venous blood was obtained for 
measurement of atrial natriuretic peptide, aldosterone and 
plasma renin activity. The pacemaker was then programmed 
to 250 beats/rain, and pacing was continued for 12 to 14 
days. Four days before the acute experiment, five dogs were 
selected at random to receive long-term therapy with 325 mg 
of aspirin administered at -4  PM daily (aspirin group) for a 
total of four doses; six dogs received no aspirin (control 
group). The last aspirin dose was administered on the 
evening before the acute study, and the animals were kept 
on a fast but allowed free access to water. 
Acute experiment. The pacemaker was briefly depro- 
grammed, and a repeat echocardiogram was acquired in sinus 
rhythm. On the day of the acute xperiment, venous blood was 
collected for measurement of salicylate levels. The pacemaker 
was again deprogrammed briefly while dogs were temporarily 
anesthetized with sodium thiopcntal (10 to 15 mg/kg) and then 
anesthetized with chloralose anesthesia (40 mgjkg, with sup- 
plemental doses as needed). Sodium thiopental was chosen 
because of its rapid onset, short half-life and minimal or no 
effect on peripheral vascular esistance or arterial blood pres- 
sure (25). Similarly, in our experience choralose has the least 
effect on canine hemodynamic function of the common anes- 
thetic agents. A flow-directed balloon-tipped pulmonary, artery 
catheter was inserted through the external jugular vein for 
measurement of intracardiac pressures and cardiac output by 
thermodilution techniques (American Edwards Laboratories). 
The femoral artery was cannulated for measurement of sys- 
temic arterial pressure and the vein for blood sampling. A 
bolus of inulin was administered followed by a constant 
infusion at 1 ml/min. A left flank incision was made and a 
ureter cannulated for urine collection. An electromagnetic 
flow probe (Carolina Instruments) was placed around the renal 
artery for measurement of renal blood flow. The pacemaker 
was reprogrammed at 220 beats/rain for the acute experiment. 
The animals were suspended in the prone position and allowed 
to equilibrate for 60 rain. 
A baseline 30-min urinary clearance was obtained, and 
bemodynamic measurements were made. Blood was collected 
for measurements of atrial natriuretic peptide, aldosterone, 
plasma renin activity, electrolytes and inulin levels. Enalaprilat 
(0.625 mg) was then administered intravenously. The enalapri- 
lat dose was chosen by utilizing the recommended initial dose 
for humans and the subsequent confirmation of a significant 
hemodynamic effect of 0.625 mg in a pilot study. Hemody- 
namic measurements were repeated at 15, 30 and 90 rain, and 
two 30-rain urinary clearances were performed with calculation 
of blood for electrolytes and inulin midway through each 
clearance. 
Cardiac hemodynamic variables assessed included mean 
arterial pressure, right atrial pressure, pulmonary capillary 
wedge pressure, cardiac output and systemic vascular esis- 
tance. Systemic vascular esistance was calculated using the 
following formula: Systemic vascular resistance = [(Mean 
arterial pressure - Right atrial pressure)/Cardiac output] × 80 
dynes.s.cm 5. Blood samples for atrial natriuretic peptide, 
aldosterone and plasma renin activity were placed in tubes 
containing ethylenediaminetetraacetic acid, immediately 
placed on ice and centrifuged at 2,500 rpm at 4°C. After 
extraction, plasma levels of atrial natriuretic peptide were 
measured by radioimmunoassay, s previously described (26). 
Plasma renin activity was determined by radioimmunoassay 
using the method of Haber et al. (27). Plasma levels of 
aldosterone were determined utilizing the method escribed 
by Sancho and Haber (28). Venous blood for sodium and 
inulin determinations was collected in heparinized tubes, 
placed on ice and centrifuged at2,500 rpm at 4°C. Plasma nd 
urinary sodium concentrations were measured using ion- 
selective lectrodes (Beckman Instruments). Glomerular fil- 
tration rate was estimated by inulin clearance. 
Statistical methods. Statistical analysis was performed us- 
ing an IBM Primer statistics package, lntragroup comparisons 
were performed using one-way analysis of variance for re- 
peated measures followed by the Student-Newman-Keuls te t 
for individual comparisons. A simple paired Student t test was 
used to compare the ejection fraction before and after pacing 
in each group. Intergroup comparisons were performed using 
an unpaired t test. In all analysis, statistical significance was 
defined as p < 0.05. 
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Resu l ts  
Effect of aspirin on cardiorenal and neurohumoral function 
in severe heart failure. Rapid ventricular pacing for 12 to 14 
days produced a similar degree of ventricular dysfunction in 
both the control and aspirin groups. Ejection fraction de- 
creased from 55 +_ 2% to 26 _+ 4% (p < 0.05) in the control 
group and from 53 + 2% to 30 _+ 4% (p < 0.05) in the aspirin 
group. Long-term administration of aspirin resulted in an 
average trough salicylate level of 3.2 _+ 0.9 mg/dl (therapeutic 
level 2 to 20 mg/dl). Salicylate levels were undetectable in the 
two control dogs where they were measured. The baseline 
hemodynamic, neurohumoral and renal profiles in the control 
and aspirin groups are depicted in Figure 1. Both groups 
demonstrated findings consistent with severe heart failure, 
with low cardiac output, increased pulmonary capillary wedge 
pressure and systemic vascular esistance and activation of 
atrial natriuretic peptide, aldosterone and plasma renin activity 
and identical renal profiles with sodium retention. There was 
no difference between the aspirin and control groups and no 
trends toward any difference in any variables. There was no 
difference in baseline serum sodium levels between the groups. 
Effect of aspirin on the acute hemodynamic and renal 
response to enalaprilat. The hemodynamic profile at baseline 
and at 15, 30 and 90 rain after enalaprilat for the control and 
aspirin groups is shown in Table 1. Mean arterial pressure, 
pulmonary capillary wedge pressure and systemic vascular 
resistance decreased to a similar degree with enalaprilat in 
both the groups. Cardiac output, renal blood flow and right 
atrial pressures did not change with enalaprilat ineither group. 
There was no significant difference between the hemodynamic 
values at baseline or at 15, 30 and 90 rain after enalaprilat 
between the groups. Although blood pressure tended to return 
closer to baseline in the aspirin group at 90 min, it was not 
significantly different between the two groups. The renal 
response to enalaprilat is depicted in Table 2. There was no 
statistically significant change in urine flow, urinary sodium 
excretion, glomerular filtration rate or fractional excretion of 
sodium with enalaprilat in either group. The change in renal 
function with enalaprilat was also analyzed and revealed no 
significant differences between groups. Although the number of 
dogs studied may be too small to reflect small differences in the 
renal response to enalaprilat, the reported renal variables reflect 
the severe sodium retention in this anesthetized model of severe 
heart failure and do not demonstrate any trends that would 
suggest an apparent difference. 
Discuss ion  
The present study demonstrates that low dose aspirin 
therapy had no adverse ffect on hemodynamic, neurohumoral 
or renal function in this well established canine model of 
severe heart failure characterized by systolic dysfunction and 
profound hemodynamic compromise analogous to that found 
in patients with severe heart failure (20-23). Furthermore, low 
dose aspirin therapy had no attenuating effect on the acute 
hemodynamic or renal response to enalaprilat. In the current 
study, enalaprilat produced the expected reductions in mean 
arterial pressure, systemic vascular esistance and filling pres- 
sures, but these effects were equivalent whether or not the 
animals had received therapy with low dose aspirin. 
High dose cyelo-oxygenase inhibitors. High doses of potent 
cyclo-oxygenase inhibitors promote sodium retention, prevent 
generation of vasodilatory prostaglandins and increase filling 
pressures in patients with severe congestive heart failure 
(14-16). Previous studies (16,29-31) have clearly demon- 
strated that the acute and chronic hemodynamic response to 
angiotensin-converting enzyme inhibition is blunted by high 
doses of potent cyclo-oxygenase inhibitors, such as indometha- 
cin, in normal subjects, hypertensive patients and patients with 
severely symptomatic heart failure (16,29-31). This suggests 
that potent cyclo-oxygenase inhibitors may block the enhanced 
production of prostaglandins mediated by the angiotensin- 
converting enzyme inhibition-induced increase in tissue levels 
of bradykinin. 
Low dose cyclo-oxygenase inhibitors. A previous tudy (32) 
in patients with mild hypertension demonstrated no adverse 
effect of low dose aspirin (75 rag/day) on the blood pressure 
response to captopril. In addition, a preliminary report (33) in 
patients with heart failure treated with enalapril showed no 
attenuation of the blood pressure-lowering effect of enalapril 
when administered with low dose (300 rag/day) aspirin. 
Aspirin dosage. We chose an aspirin dose equivalent to the 
higher end of the range reported to be effective for the primary 
and secondary prevention of ischemic events in patients with 
coronary artery disease but low when compared with equiva- 
lent doses of other nonsteroidal nti-inflammatory drugs al- 
ready known to be detrimental in such patients. By adminis- 
tering the drug for 4 days, we allowed a steady state to occur 
and a reasonable time for any effect on prostaglandin produc- 
tion to develop. 
In contrast, Hall et al. (19) reported a significant blunting of 
the response to enalapril n patients with severe heart failure 
who received asingle dose of aspirin with or 1 to 3 days before 
the administration f enalapril. Furthermore, Hall and Ru- 
dolph (34) subsequently reported a decrease in serum sodium 
concentration associated with a single dose of aspirin in 
patients that was not observed with long-term low dose aspirin 
therapy in experimental heart failure in the current study. The 
reasons for the conflicting results reported by Hall et al. and 
those found in the current study may be multiple. The present 
study was performed uring experimental heart failure with no 
other therapy, whereas the study of Hall et al. was performed 
in 18 patients who received different herapies in a complex 
schemata in different orders on different days during a pro- 
longed hospital period. The 9 patients who received enalapril 
alone received it on the first day of the study and were 
compared with 18 patients who received enalapril along 
with, or 24 h after, aspirin on day 2 or 3 (and half of these 
patients had received enalapril previously). During the 3 days 
of the study, the patients were continuously monitored with 
Swan-Ganz catheters. Conceivably, previous therapy with 
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Figure 1. Baseline hemodynamic (A), hormonal (B) and renal (C) 
function in the aspirin (ASA) versus control group. Aldo = plasma 
aldosterone; ANP = atrial natriuretic peptide; CO = cardiac output; 
FENa = fractional excretion of sodium (Na); GFR = glomerular 
filtration rate; MAP = mean arterial pressure; PCWP = pulmonary 
capillary wedge pressure; PRA = plasma renin activity; RBF - renal 
blood flow; SVR = systemic vascular resistance; U£ = urinary flow; 
UNaV = urinary sodium excretion. 
enalapril, dietary and activity modification or group differences 
in the 9 patients with enalapril alone versus the 18 patients with 
enalapril and aspirin could affect the response to angiotensin- 
converting enzyme inhibition. The patients in the study by Hall 
et al. had been previously treated with diuretic drugs and may 
have been more decompensated, more dependent on activa- 
tion of vasodilatory prostaglandins and, thus, more sensitive to 
aspirin. 
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Table 1. Acute Hemodynamic Response to Enalaprilat in a Canine Model of Severe Heart Failure 
Time After Enalaprilat Administration 
Baseline 15 min 30 min 90 ±in 
MAP (ram Hg) 
Control group 114 ± 6 95 -+ 6* 102 + 7* 
ASA group 110 2 7 96 ± 8* 99 + 9* 
CO (liters/±in) 
Control group 1.66 + 0.25 1.83 ± 11.28 1.55 + 0.22 
ASA group 1.87 + 11.24 1.97 ± 11.22 1.96 + 0.29 
SVR (dynes.s'cm s) 
Control group 5,562 + 908 4,205 + 707* 5,127 -+ 548 
ASA group 4,5/11 + 538 3,664 + 515" 3,928 ± 616 
RAP (mm Hg) 
Control group 10.2 _+ 1.7 9.42 +_ 1.5 9.25 + 1.6 
ASA group 10.2 ± 2.0 9.50 ± 1.9 9.50 ± 1.8 
PCWP (ram Hg) 
Control group 26.0 + 1.4 22.3 + 1.6" 23.1 ± 1.4" 
ASA group 26.0 + 2.0 22.2 +_ 1.7" 23.1/+ 1.7' 
RBF (ml/min) 
Control group 85 + 19 96 z 25 94 ± 24 
ASA group 1311 + 32 145 z 36 149 + 34 
102 + 9 
108 + 8 
1.27 ± 0.17 
1.89 _+ 0.31 
5,958 ± 621 
4,652 ± 881 
11.6 + 2.0 
10.0 ± 1.9 
24.6 ± 2.7 
22.7 -+ 1.7 
89 + 3l 
168 + 37 
*p < 11.05 vcrsus baseline. Data presented are mean value + SEM. ASA - aspirin; CO - cardiac output; MAP = 
mean arterial pressure; PCWP pulmonary capillary wedge pressure; RAP right atrial pressure; RBF - renal blood 
flow; SVR = systemic vascular resistance. 
Findings in anesthetized animals cannot always be consid- 
ered representative of conditions in conscious humans. The 
present study was performed during anesthesia maintained 
with chloralose. This agent is recognized to produce less 
depression of baroreceptor and chemoreceptor reflexogenic 
responsiveness and does not appear to exert a marked or 
sustained depression of cardiac function (35). Because enala- 
prilat induced similar quantitative and qualitative effects in 
anesthetized ogs and conscious humans, it is unlikely that the 
presence of anesthesia profoundly influenced our findings. 
Unlike the Hall et al. (19) study, the present study used 
Table 2. Acute Renal Response to Enalaprilat in a Canine Model 
of Severe Heart Failure 
Enalaprilat Administration 
Baselinc 30 min 60 min 
Urinary volumc 
Control group 0.14 */I .04 0.17 + 0.06 0.18 z 0.08 
ASA group 0.(19 - 0.01 0.11 _+ 0.04 I).09 z 0.03 
UNaV 
Control group 3.8 _+ 1.8 6.6 + 3.4 4.9 + 2.5 
ASA group 4.1 + 2.0 9.7 + 6.7 9.5 _+ 2.5 
FENa 
Control group 0.16 + 0.09 0.31 + 1/.14 0.22 _+ 11.11 
ASA group 0.16 + 0.06 0.23 + 11.15 0.23 -+ 0.10 
GFR 
Control group 17.0 + 3.3 13.3 - 2.6 15.5 _+ 2.9 
ASA group 16.8 _+ 2.9 16.6 _-_ 5.9 18.1 + 5.5 
*p < 0.05 versus baseline. Data presented are mean value ± SEM. ASA 
aspirin; GFR - glomerular filtration rate; FENa = fractional excretion of 
sodium; UNag = urinary sodium excretion. 
intravenous administration of angiotensin-converting enzyme 
inhibition to ensure that the response was independent of 
factors that may influence absorption and strictly controlled 
competing influences and exogenous factors. It is possible that 
the systemic effects of oral enalapril differ from those of 
intravenous enalaprilat. However, although only -60% of oral 
enalapril is absorbed by humans, it then requires deesterifica- 
tion by the intact liver and kidneys to the active form (enala- 
prilat), which supports our contention of a more reliable test 
condition with direct intravenous administration of enalaprilat. 
Although the full resolution of this issue requires more study in 
humans, the current study importantly supports the lack of 
detrimental action of low dose aspirin on the acute hemody- 
namic response to angiotensin-converting enzyme inhibition. 
The effect of low dose aspirin on the chronic hemodynamic 
response to angiotensin-converting enzyme inhibition in pa- 
tients with heart failure is unknown. A preliminary report (36) 
of a subgroup analysis of patients in the Studies of Left 
Ventricular Dysfunction study did reveal a trend toward a 
decreased mortality benefit in patients treated with aspirin. 
However, the ability of such an analysis to separate the effects 
of aspirin alone from the general differences in mortality as a 
result of the higher prevalence of coronary artery or diffuse 
atherosclerotic disease, or both, in aspirin-treated patients is 
unclear. The full resolution of this question will require more 
study. 
Conclusions. The current findings suggest that low dose 
aspirin therapy in heart failure is not detrimental and does not 
antagonize the short-term hemodynamic effects of angiotensin- 
converting enzyme inhibition. Further investigation into the 
chronic interaction between aspirin and angiotensin- 
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converting enzyme inhibition in patients with left ventricular 
dysfunction should be performed before abandoning coadmin- 
istration of these two etficacious agents. 
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